Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00794352 · ClinicalTrials.gov registry record

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

A clinical trial of Multiple Sclerosis and Central Nervous System Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
2,400
Enrollment target
1
Study location

NCT00794352: Recruiting study of Multiple Sclerosis and Central Nervous System Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00794352 is a study of Multiple Sclerosis and Central Nervous System Disease that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,400 participants, above the 577-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (316% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00794352, a study of Multiple Sclerosis and Central Nervous System Disease, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
2,400 participants
Enrollment target
1
Study location

Study Summary

Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least 12 years old. Subjects will either have symptoms of immune-related CNS damage, or will be healthy volunteers selected for comparison purposes. Study participants will visit the NIH Clinical Center on an outpatient basis for an initial evaluation visit. During the visit, patients will provide a comprehensive medical history and undergo a neurological examination, and will provide blood samples for research purposes. The healthy volunteers will be asked to schedule a return visit for a magnetic resonance imaging (MRI) procedure, and may be asked to undergo other tests requested by the study researchers on an as-needed basis. The group of patients with symptoms of immune-related CNS damage will be asked to undergo a series of tests, including the following: * MRI procedures, with a minimum of three brain MRIs and one spinal cord MRI taken approximately 4 weeks apart * A diagnostic lumbar puncture, performed on an outpatient basis * Tests of brain and vision activity * Additional blood and tissue samples Patients with symptoms of immune-related CNS damage may be offered the opportunity to participate in additional followup tests with NIH researchers. ...

Primary Outcome

1\. Sustained (i.e. \> 3 months) progression of disability as measured by =\> 0.5 CombiWISE points or 2. Development of new/clearly enlarged distinct lesions on T2WI

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 2,400 participants
Start Date 2008-10-01

What NCT00794352 shows while recruiting

NCT00794352 is an observational study that tracks outcomes without assigning an intervention. Its 2,400 participants enrollment target places it among the larger protocols in the corpus, above the 577-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (316% higher).

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT00794352 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00794352 about?

NCT00794352 is a clinical study titled "Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System". Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This ...

What is the current status of trial NCT00794352?

This trial is currently recruiting. The enrollment target is 2,400 participants. The study started on 2008-10-01.

What conditions does trial NCT00794352 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Central Nervous System Disease.

Who is sponsoring clinical trial NCT00794352?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00794352 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00794352's enrollment target sits among peer trials

2,400 13th of 315 higher than 303 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05185440 · 2,400 participants · NA

    Reducing Alcohol Involved Sexual Violence in Higher Education

  • NCT05285527 · 2,400 participants · NA

    MiSight 1 Day Safety Post-Approval Study

  • NCT05738330 · 2,400 participants · NA

    Symptom Monitoring in Hemodialysis

  • NCT05833360 · 2,400 participants

    Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00794352, the US trial registry maintained by the National Library of Medicine. NCT00794352 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.